A Phase 2 interventional study of Sarilumab and Prednisone in Uveitis, sponsored by Sanofi. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Uveitis with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Uveitis · Turkey.
Among the 11 studies in Uveitis with a site in Turkey, this one is the only one that started in 2013, is the only one in phase 2, and was the 7th registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →2 of the 11 studies in Uveitis with a site in Turkey are open now. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Turkey, United States, Belgium and 2 more countries
Ages 1–16
University of Siena · Sites in Turkey, Algeria, Australia and 19 more countries
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 118 across the 9 interventional studies, 1,895 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 7 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Uveitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Uveitis with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU).
Secondary Objectives:
To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant therapy.
To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with anti-drug antibodies (ADA).
The total duration per participant was up to 58 weeks, which included a 2 week screening period, 16 weeks principal treatment period (Part A), 34 weeks extension treatment period (Part B) or open label treatment period (Part C), and 6 weeks after last treatment administration.
Participants with decrease in vitreous haze (VH) ≥2; or corticosteroids dose \<10 mg/day at Week 16 were considered as responders. Participants who did not complete the principal treatment period (Part A) due to lack of efficacy; or no decrease in VH ≥2 and corticosteroids dose ≥10 mg/day at Week 16; or no decrease in VH ≥2 and corticosteroids dose missing at Week 16; or non-responder according to medical review, were considered as non-responders.
Responder participants, observed at Week 16 (at the end of Part A), were invited to continue in the extension treatment period (Part B).
Non-responder participants, observed within the first 16 weeks, were offered to be treated by open-label sarilumab (Part C).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
Drug: Sarilumab · Drug: Prednisone · Drug: Methotrexate · Drug: Folic/folinic acid · Other: Placebo (for Sarilumab)
Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
Drug: Sarilumab · Drug: Prednisone · Drug: Methotrexate · Drug: Folic/folinic acid
Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Also known as: SAR153191/REGN88
Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Drug page: Leucovorin
Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16
At least 2-step reduction in VH per central review from baseline was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) are equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Participants with prednisone dose \<10 mg/day (or equivalent oral corticosteroid) were also evaluated.
Time frame: Week 16
Change From Baseline in VH Scale at Week 16
Change from baseline in VH scale was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) were equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Least squares (LS) mean was calculated using mixed model for repeated measurements (MMRM) model with treatment groups, visits and visit-by-treatment groups interaction as fixed categorical effects as well as fixed continuous covariate of baseline adjudicated VH.
Time frame: Baseline to Week 16
Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16
Participants with AC cell score = 0 or with ≥2 step reduction from baseline at Week 16 were evaluated. Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: grade 0 = no cells; grade +0.5 = 1 - 5 cells; grade +1 = 6 - 25 cells; grade +2= 26 - 50 cells; grade +3 = too many to count.
Time frame: Week 16
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16
BCVA score is based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters, and then at 1 meter. The range of ETDRS is 0 to 100 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline BCVA.
Time frame: Baseline to Week 16
Change From Baseline in Central Retinal Thickness (CRT) At Week 16
CRT was measured by spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.
Time frame: Baseline to Week 16
Percent Change From Baseline in CRT at Week 16
CRT was measured by SD-OCT, a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.
Time frame: Baseline to Week 16
Percentage of Participants With CRT Thickness <300 Microns at Week 16
Time frame: Week 16
Percentage of Participants Without Retinal Vessel Leakage on Fluorescein Angiography (FA) at Week 16
Time frame: Week 16
Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16
Participants with prednisone dose ≤5 mg/day (or equivalent oral corticosteroid) at Week 16 were evaluated.
Time frame: Week 16
Pharmacokinetics (PK) Assessment: Serum Functional Sarilumab Concentration
Serum functional (unbound) sarilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method with a lower limit of quantification (LLOQ) of 294 ng/mL. Concentrations below LLOQ were set to zero for samples at predose. Post-treatment concentrations below LLOQ were replaced by LLOQ/2. The samples were considered non-eligible for the analysis if the previous dosing time was \<11 days or \>17 days before the sampling time for every other week regimens.
Time frame: Predose on Day 1 (Baseline), Week 2, 4, 8, 12, 16, 24, 36, 52, and end of study (EOS) (Week 56)
The study was conducted at 18 centers in 6 countries. A total of 82 participants were screened between 30 October 2013 and 17 March 2015 of whom 58 participants were randomized and 24 were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Placebo | Sarilumab 200 mg q2w | Sarilumab 200 mg q2w (Open-Label Treatment) |
|---|---|---|---|
| Started | 20 | 38 | 0 |
| Completed | 13 | 28 | 0 |
| Not completed | 7 | 10 | 0 |
| Withdrew: Adverse event | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 6 | 6 | 0 |
| Withdrew: Other than specified above | 0 | 1 | 0 |
| Milestone | Placebo | Sarilumab 200 mg q2w | Sarilumab 200 mg q2w (Open-Label Treatment) |
|---|---|---|---|
| Started | 8 | 22 | 0 |
| Completed | 7 | 12 | 0 |
| Not completed | 1 | 10 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 7 | 0 |
| Withdrew: Other than specified above | 0 | 1 | 0 |
| Milestone | Placebo | Sarilumab 200 mg q2w | Sarilumab 200 mg q2w (Open-Label Treatment) |
|---|---|---|---|
| Started | 0 | 0 | 21 |
| Completed | 0 | 0 | 13 |
| Not completed | 0 | 0 | 8 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
At least 2-step reduction in VH per central review from baseline was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) are equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Participants with prednisone dose \<10 mg/day (or equivalent oral corticosteroid) were also evaluated.
| Percentage of participants | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16 | 30.0 | 46.1 |
Change from baseline in VH scale was evaluated on Miami 9-step scale. VH is the obscuration of fundus by vitreous cells and protein exudation. Each of the 9-step scale (from grade 0 \[low opacity\] to 8 \[more opacity\]) images (in increasing order of opacity) were equivalent to approximately 0.3 log units of degradation in visual acuity based on the Bangerter calibration. Least squares (LS) mean was calculated using mixed model for repeated measurements (MMRM) model with treatment groups, visits and visit-by-treatment groups interaction as fixed categorical effects as well as fixed continuous covariate of baseline adjudicated VH.
| units on a scale | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Change From Baseline in VH Scale at Week 16 | -0.1 ± 0.23 | -0.9 ± 0.16 |
Participants with AC cell score = 0 or with ≥2 step reduction from baseline at Week 16 were evaluated. Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: grade 0 = no cells; grade +0.5 = 1 - 5 cells; grade +1 = 6 - 25 cells; grade +2= 26 - 50 cells; grade +3 = too many to count.
| Percentage of participants | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Percentage of Participants With Anterior Chamber (AC) Cell Score = 0 or At Least 2-step Reduction in Score at Week 16 | 86.7 | 86.2 |
BCVA score is based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters, and then at 1 meter. The range of ETDRS is 0 to 100 letters. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline BCVA.
| units on a scale | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 16 | 3.5 ± 1.84 | 9.3 ± 1.36 |
CRT was measured by spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.
| µm (microns) | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) At Week 16 | -8.9 ± 11.46 | -35.4 ± 8.36 |
CRT was measured by SD-OCT, a non-invasive diagnostic system providing high-resolution imaging sections of the retina. All images were transmitted to the central reading center. SD-OCT was performed in the study eye after pupil dilation. LS mean was calculated using MMRM model with treatment groups, randomization strata of VH level (\<4, \>=4), visits and visit-by-treatment groups interaction as fixed categorical effects, as well as, fixed continuous covariate of baseline CRT.
| percent change | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Percent Change From Baseline in CRT at Week 16 | 0.0 ± 2.90 | -6.4 ± 2.15 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Participants with prednisone dose ≤5 mg/day (or equivalent oral corticosteroid) at Week 16 were evaluated.
| Percentage of participants | Placebo (Part A) | Sarilumab 200 mg q2w (Part A) |
|---|---|---|
| Percentage of Participants With Prednisone Dose of ≤5 mg/Day (or Equivalent Oral Corticosteroid) at Week 16 | 40.0 | 41.4 |
Serum functional (unbound) sarilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method with a lower limit of quantification (LLOQ) of 294 ng/mL. Concentrations below LLOQ were set to zero for samples at predose. Post-treatment concentrations below LLOQ were replaced by LLOQ/2. The samples were considered non-eligible for the analysis if the previous dosing time was \<11 days or \>17 days before the sampling time for every other week regimens.
| ng/mL | Sarilumab 200 mg q2w (Part A + Part B) |
|---|---|
| At Baseline | 0.0 ± 0.0 |
| At Week 2 | 7383.3 ± 6547.1 |
| At Week 4 | 9876.6 ± 8262.9 |
| At Week 8 | 15958.9 ± 12813.1 |
| At Week 12 | 19705.2 ± 15480.9 |
| At Week 16 | 19598.4 ± 17280.8 |
| At Week 24 | 22406.8 ± 14584.2 |
| At Week 36 | 24375.4 ± 19121.7 |
| At Week 52 | 25046.0 ± 17870.7 |
| EOS (Week 56) | 1730.0 ± NA |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (6 weeks after the last treatment administration [Week 56]) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Part A + Part B) | — | 2/20 (10%) | 13/20 (65%) |
| Sarilumab 200 mg q2w (Part A+ Part B) | — | 5/38 (13.2%) | 25/38 (65.8%) |
| Sarilumab 200 mg q2w: Open-Label Treatment (Part C) | — | 0/21 (0%) | 15/21 (71.4%) |
| Event | Placebo (Part A + Part B) | Sarilumab 200 mg q2w (Part A+ Part B) | Sarilumab 200 mg q2w: Open-Label Treatment (Part C) |
|---|---|---|---|
| Abortion inducedSurgical and medical procedures | 0/20 | 2/38 | 0/21 |
| Staphylococcal sepsisInfections and infestations | 1/20 | 0/38 | 0/21 |
| Intraocular pressure increasedInvestigations | 1/20 | 0/38 | 0/21 |
| HypoaesthesiaNervous system disorders | 1/20 | 0/38 | 0/21 |
| Deep vein thrombosisVascular disorders | 1/20 | 0/38 | 0/21 |
| NeutropeniaBlood and lymphatic system disorders | 0/20 | 1/38 | 0/21 |
| UveitisEye disorders | 0/20 | 1/38 | 0/21 |
| Liver function test increasedInvestigations | 0/20 | 1/38 | 0/21 |
| Event | Placebo (Part A + Part B) | Sarilumab 200 mg q2w (Part A+ Part B) | Sarilumab 200 mg q2w: Open-Label Treatment (Part C) |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/20 | 2/38 | 6/21 |
| Accidental overdoseInjury, poisoning and procedural complications | 4/20 | 3/38 | 1/21 |
| UveitisEye disorders | 2/20 | 6/38 | 1/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/20 | 4/38 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 1/38 | 3/21 |
| Behcet's syndromeVascular disorders | 1/20 | 1/38 | 3/21 |
| NeutropeniaBlood and lymphatic system disorders | 0/20 | 4/38 | 1/21 |
| InfluenzaInfections and infestations | 0/20 | 4/38 | 2/21 |
| HeadacheNervous system disorders | 2/20 | 4/38 | 2/21 |
| PyrexiaGeneral disorders | 2/20 | 0/38 | 0/21 |
| Age, Continuous(years) | Placebo | Sarilumab 200 mg q2w | Total |
|---|---|---|---|
| Mean | 41.5 ± 13.0 | 39.3 ± 15.3 | 40.0 ± 14.5 |
| Sex: Female, Male(Participants) | Placebo | Sarilumab 200 mg q2w | Total |
|---|---|---|---|
| Female | 13 | 23 | 36 |
| Male | 7 | 15 | 22 |
The record gives a start of Oct 2013, a primary completion of Jul 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 11 months after primary completion. A results delay was requested in Mar 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab